Company intelligence / Profile preview

MZE Biotech

San Diego, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

MZE Biotech is a preclinical-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for cancer and autoimmune diseases. The company's primary research efforts center on targeting the MALT1 protease, a key regulator of the NF-κB signaling pathway involved in immune cell activation. Their lead candidate, MZE-101, is a selective MALT1 inhibitor designed to treat aggressive B-cell lymphomas and various inflammatory conditions. Headquartered in San Diego with operations in Shanghai, MZE Biotech leverages a global R&D model to advance its pipeline of targeted therapies.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MZE Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MZE Biotech.

Explore the full profile